Exosomal miR-19a derived from melanoma cell promotes the vemurafenib resistance of malignant melanoma through directly targeting LRIG1 to reactivate AKT and MAPK pathway
Wenkang Luan, Lu Xu, Huiyong Peng, Xuanlin Shen, Min Rao, Hongru Ruan
Topics & Concepts
VemurafenibMelanomaMAPK/ERK pathwayCancer researchMedicineProtein kinase BPI3K/AKT/mTOR pathwayMetastatic melanomaSignal transductionBiologyCell biologyMelanoma and MAPK PathwaysCell Adhesion Molecules ResearchImmunotherapy and Immune Responses